期刊文献+

HRCT征象联合TTF-1用于区分不同浸润程度的磨玻璃结节样肺腺癌 被引量:1

HRCT Signs Combined with TTF-1 were Used to Distinguish Nodular Ground-Glass Lung Adenocarcinoma with Different Degrees of Infiltration
下载PDF
导出
摘要 目的分析高分辨率CT(HRCT)征象联合肺癌相关临床指标与不同浸润程度的磨玻璃结节样肺腺癌(GGNs)的相关性。方法回顾144例经手术和病理确诊为GGNs的患者临床资料,分为浸润前病变(PI)组(n=35)、微浸润性腺癌(MIA)组(n=46)和浸润性腺癌(IA)组(n=63),并通过单因素分析和无序多分类logistic回归分析比较三组患者的HRCT征象。收集144例患者的免疫组化切片,通过Image J 1.8.0分析肺癌相关临床指标:癌胚抗原(CEA)、表皮生长因子受体(EGFR)、血管内皮生长因子(VEGF)、天冬氨酸蛋白酶A(NapsinA)、角蛋白7(CK7)、甲状腺转录因子-1(TTF-1)、CK5/6、肿瘤蛋白p53(P53)、细胞增殖相关抗原Ki67和肿瘤蛋白p40(P40)的光密度(OD)值以计算这些基因的相对表达量,并分析这些指标与HRCT征象的相关性。结果单因素分析显示,三组患者的GGNs大小和密度、分叶征、毛刺征、胸膜牵拉征、瘤-肺边界、微血管穿行征和空气支气管征均有显著差异(P<0.05)。此外,高表达的TTF-1与不同的HRCT征象密切相关,提示TTF-1可能是GGNs患者中HRCT征象异常的潜在因素。结论HRCT征象联合TTF-1可用于进一步区分GGNs中的PI、MIA和IA病变。 Objective The correlation between high resolution computed tomography(HRCT) images combined with clinical indicato rs related to lung cancer and small ground glass nodule-like lung adenoca rcinoma(GGNs) with different degrees of infiltration was analyzed.Methods A retrospective study of 144 patients diagnosed as GGNs by su rgery and pathology,were divided into pre-invasive lesion(PI) group(n=35),micro-invasive adenocarcinoma(MIA) group(n=46),and invasive adenocarcinoma(IA) group(n=63).The HRCT signs of the three groups of patients were compared by univariate analysis and disordered multivariate logistic regression analysis.Immunohistochemical sections were collected from 144 patients,image J 1.8.0 was used to analyze the optical density(Optical Density,OD) value of some clinical indicators of lung cancer,including Carcinoembryonic Antigen(CEA),Epidermal G rowth Factor Receptor(EGFR),Vascular endothelial Growth Factor(VEGF),Aspartic protease A(N a psinA),Keratin 7(CK7),Thyroid tra nscription factor-1(TTF-1),CK5/6,Tumor protein p53(p53),cell prolife rationrelated antigen Ki67(Ki67) and Tumor protein p40(p40) to calculate the relative expression of these genes,and the correlation between these indicators and HRCT signs were analyzed.Results Univa riate analysis showed that there were significant differences in the size and density of GGNs,lobular sign,spicule sign,pleural traction sign,tumor-lung interface,microvascular penetrating sign,and bronchial air sign in the three groups(all P<0.05).In addition,the high expression of TTF-1 is closely related to diffe rent HRCT signs,suggesting that TTF-1 may be a potential factor for abnormal HRCT signs in GGNs patients.Conclusion HRCT signs combined with TTF-1 can be used to further distinguish PI,MIA and IA lesions.
作者 张榕 杨少民 郭保亮 欧阳富盛 刘子蔚 周翠铷 肖强 胡秋根 ZHANG Rong;YANG Shao-min;GUO Bao-liang;OUYANG Fu-sheng;LIU Zi-wei;ZHOU Cui-ru;XIAO Qiang;HU Qiu-gen(Department of Radiology,Shunde Hospital,Southern Medical University(the First People’s Hospital of Shunde,Foshan),Foshan 528308,Guangdong Province,China;Department of Respiratory,Shunde Hospital,Southern Medical University(the First People’s Hospital of Shunde,Foshan),Foshan 528308,Guangdong Province,China)
出处 《中国CT和MRI杂志》 2021年第9期38-43,共6页 Chinese Journal of CT and MRI
基金 佛山市科技创新项目(FSOAA-KJ218-1301-0014) 广东省医学科学技术研究基金项目(B2019033)。
关键词 不同浸润程度GGNs HRCT征象 肺癌相关免疫组化指标 GGNs with Different Degrees of Infiltration HRCT Signs Lung Cancer-Related Immunohistochemical Indicators
  • 相关文献

参考文献3

二级参考文献33

  • 1陈威威,初建国,温智勇,康枫,齐旭红,任冰.周围型肺癌的CT征象、病理表现与C-erbB-2、PCNA表达的相关性研究[J].中国CT和MRI杂志,2007,5(1):26-28. 被引量:14
  • 2Ciardiello F, Tortora G. EGFR antagonists in cancer treatment[J]. N Engl J Med. 2008 Mar 13;358(11):1160-74.
  • 3Soo RA, Loh M, Mok TS, et al. Ethnic differences in survival outcome in patients with advanced stage non-small cell lung cancer: results of a meta-analysis of randomized controlled trials [J]. J Thorac Oncol, 2011Jun; 6(6):1030-8.
  • 4Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first- line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer(EURTAC): a multicentre, open-label, randomised phase 3 trial[J]. Lancet Oncol. 2012 Mar; 13(3):239-46.
  • 5Jawhari AU, Farthing MJ, Pignatelli M. /he E-cadherin /epidermal growth factor receptor interaction: a hypothesis of reciprocal and reversible control of intercellular adhesion and cell proliferation[J]. J Pathol. 1999 Jan; 187(2):155-7.
  • 6Perentes JY, Kirkpatrick ND, Nagano S, et al. Cancer cell associated MT1-MMP promotes blood vessel invasion and distant metastasis in triple- negative mammary tumors[J]. Cancer Res. 2011 Jul 1; 71(13):4527-38.
  • 7Siena S, Sartore-Bianchi A, Di Nicolantonio F, et al. Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer [J]. J Natl Cancer Inst. 2009 Oct 7; 101(19):1308-24.
  • 8Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small cell lung cancer with mutated EGFR[J]. N Engl J Med. 2010 Jun 24;362(25):2380-8.
  • 9Garassino Me, Martelli O, Bettini A, et al. Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small- cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial[J]. Lancet Oncol. 2013 Sep; 14(10):981-8.
  • 10Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma[J]. N Engl J Med. 2009 Sep 3;361(10):947-57.

共引文献36

同被引文献17

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部